Use of atypical antipsychotic medications in adolescent psychiatric inpatients: A comparison with inpatients who did not receive antipsychotic medications during their stay

International Journal of Clinical Practice

Volumn 61, Issue 6, 2007, Pages 896-902

  Pogge, D L ^a,b   Young, K ^b   Insalaco, B ^b   Harvey, P D ^c  

^a Four Winds Hospital   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC AGENT; LITHIUM; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; BIPOLAR DISORDER; CLINICAL EXAMINATION; CLINICAL FEATURE; CONDUCT DISORDER; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; ETHNIC DIFFERENCE; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL HOSPITAL; MENTAL PATIENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SAMPLING; SEX DIFFERENCE;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES;

EID: 34248345423     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01379.x     Document Type: Article

References (16)

1. Martin A, Leslie D. Trends in psychotropic medication costs for children and adolescents, 1997-2000. Arch Pediatr Adolesc Med 2003 157 : 997 1004.
2. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML. Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 2002 12 : 221 9.
3. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004 158 : 753 9.
4. Rawal PH, Lyons JS, MacIntyre JC, Hunter JC. Regional variation and clinical indicators of antipsychotic use in residential treatment: a four-state comparison. J Behav Health Serv Res 2004 31 : 178 88.
5. Staller JA, Wade MJ, Baker M. Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. J Child Adolesc Psychopharmacol 2005 15 : 57 61.
6. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006 63 : 679 85.
7. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004 29 : 133 45.
8. Aman MG, DeSmedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002 159 : 1337 46.
9. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004 161 : 414 25.
10. Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 2004 6 : 33 44.
11. Pogge DL, Singer MB, Harvey PD. Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients. J Child Adolesc Psychopharmacol 2005 15 : 901 12.
12. Derogatis LR. Hopkins Psychiatric Rating Scale. Baltimore, MD : Clinical Psychometric Research, 1983.
13. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001 158 : 131 4.
14. Adson DE, Kushner MG, Eiben KM et al. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 2004 19 : 121 6.
15. Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI resistant major depressive disorder. J Clin Psychiatry 2004 65 : 217 21.
16. Rapaport MH, Gharabawai GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006 31 : 2505 13.